Johns Hopkins Bloomberg School of Public Health. netSPEAR 4th Annual Network Conference. 9-10 November 2006 ... Expected health impact equal to or better than ...
Public-Private Product Development Partnerships for Global Health R&D: Issues & Challenges Suerie Moon Giorgio Ruffolo Doctoral Fellow in Sustainability Science
(HIV neg) 95% CI. VE (%) placebo rate/1000. vaccine n=19,122. endpoint ... Effectiveness of vaccine in HIV. Effect of vaccine on carriage of pneumococci ...
The leading cause of infectious death in children 5 years of ... Measles and Pertussis vaccines have already reduced deaths and cases of childhood pneumonia ...
34% of WHO pneumonia cases have evidence of consolidation on chest x-ray ... Odds Ratio and 95% CI ... 1 WHO Position Paper on Haemophilus Influenzae type B ...
II - Rota clinical trials. Management Committe recommendations. Proposed timeline ... Phase 3 clinical trials of Merck vaccine in Africa and Asia. Time-sensitivity ...
IMS: Presentation by Peter Stephens 26/2/07 ... John Hurvitz, Covington & Burling. Steve Jarrett, UNICEF Supply Division ... Edward Wilson, John Snow, Inc. 43 ...
Kate O'Brien, Deputy Dir. Farzana Muhib, Coordinator. ADIP's ... by larger host institution Johns Hopkins SPH that provides flexibility and support ...